KR930703339A - 씨(c)-키트 수용체의 리간드 및 그의 이용방법 - Google Patents
씨(c)-키트 수용체의 리간드 및 그의 이용방법Info
- Publication number
- KR930703339A KR930703339A KR1019930700578A KR930700578A KR930703339A KR 930703339 A KR930703339 A KR 930703339A KR 1019930700578 A KR1019930700578 A KR 1019930700578A KR 930700578 A KR930700578 A KR 930700578A KR 930703339 A KR930703339 A KR 930703339A
- Authority
- KR
- South Korea
- Prior art keywords
- effective amount
- patient
- kit ligand
- pharmaceutical composition
- polypeptide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 238000000034 method Methods 0.000 title claims abstract 30
- 239000003446 ligand Substances 0.000 title claims 4
- 108010039445 Stem Cell Factor Proteins 0.000 claims abstract 56
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract 26
- 229920001184 polypeptide Polymers 0.000 claims abstract 24
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract 24
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract 24
- 108020004707 nucleic acids Proteins 0.000 claims abstract 19
- 102000039446 nucleic acids Human genes 0.000 claims abstract 19
- 150000007523 nucleic acids Chemical class 0.000 claims abstract 19
- 125000003275 alpha amino acid group Chemical group 0.000 claims abstract 3
- 239000003937 drug carrier Substances 0.000 claims abstract 3
- 239000012634 fragment Substances 0.000 claims abstract 2
- 108090000623 proteins and genes Proteins 0.000 claims description 14
- 210000001185 bone marrow Anatomy 0.000 claims description 13
- 210000003630 histaminocyte Anatomy 0.000 claims description 12
- 210000004027 cell Anatomy 0.000 claims description 9
- 102000004169 proteins and genes Human genes 0.000 claims description 9
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 claims description 7
- 230000035755 proliferation Effects 0.000 claims description 4
- 108010002386 Interleukin-3 Proteins 0.000 claims description 3
- 230000000694 effects Effects 0.000 claims description 3
- 239000000463 material Substances 0.000 claims description 2
- 102100020880 Kit ligand Human genes 0.000 claims 51
- 239000000203 mixture Substances 0.000 claims 16
- 241000124008 Mammalia Species 0.000 claims 12
- 108020004414 DNA Proteins 0.000 claims 7
- 102000053602 DNA Human genes 0.000 claims 7
- 230000008827 biological function Effects 0.000 claims 6
- 230000002708 enhancing effect Effects 0.000 claims 6
- 208000032839 leukemia Diseases 0.000 claims 6
- 210000003527 eukaryotic cell Anatomy 0.000 claims 5
- 239000000126 substance Substances 0.000 claims 5
- 230000004069 differentiation Effects 0.000 claims 4
- 210000003958 hematopoietic stem cell Anatomy 0.000 claims 4
- 229940104230 thymidine Drugs 0.000 claims 4
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 claims 3
- 208000028389 Nerve injury Diseases 0.000 claims 3
- 208000007502 anemia Diseases 0.000 claims 3
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 claims 3
- 230000004071 biological effect Effects 0.000 claims 3
- 201000002364 leukopenia Diseases 0.000 claims 3
- 231100001022 leukopenia Toxicity 0.000 claims 3
- 230000008764 nerve damage Effects 0.000 claims 3
- 230000002685 pulmonary effect Effects 0.000 claims 3
- 238000011084 recovery Methods 0.000 claims 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims 2
- 208000030507 AIDS Diseases 0.000 claims 2
- 108020005544 Antisense RNA Proteins 0.000 claims 2
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 claims 2
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 claims 2
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 claims 2
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 claims 2
- 101000716729 Homo sapiens Kit ligand Proteins 0.000 claims 2
- 206010020751 Hypersensitivity Diseases 0.000 claims 2
- 108010002352 Interleukin-1 Proteins 0.000 claims 2
- 208000026935 allergic disease Diseases 0.000 claims 2
- 230000007815 allergy Effects 0.000 claims 2
- 238000002512 chemotherapy Methods 0.000 claims 2
- 239000003184 complementary RNA Substances 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 210000003013 erythroid precursor cell Anatomy 0.000 claims 2
- 230000001747 exhibiting effect Effects 0.000 claims 2
- 230000003700 hair damage Effects 0.000 claims 2
- 239000012216 imaging agent Substances 0.000 claims 2
- 230000001939 inductive effect Effects 0.000 claims 2
- 230000002401 inhibitory effect Effects 0.000 claims 2
- 201000001441 melanoma Diseases 0.000 claims 2
- 239000000049 pigment Substances 0.000 claims 2
- 239000013612 plasmid Substances 0.000 claims 2
- 230000005855 radiation Effects 0.000 claims 2
- 210000000278 spinal cord Anatomy 0.000 claims 2
- 230000001629 suppression Effects 0.000 claims 2
- 229940124597 therapeutic agent Drugs 0.000 claims 2
- 210000001519 tissue Anatomy 0.000 claims 2
- 238000002054 transplantation Methods 0.000 claims 2
- 208000029483 Acquired immunodeficiency Diseases 0.000 claims 1
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims 1
- 206010002961 Aplasia Diseases 0.000 claims 1
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims 1
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims 1
- 108090000790 Enzymes Proteins 0.000 claims 1
- 102000004190 Enzymes Human genes 0.000 claims 1
- 241000238631 Hexapoda Species 0.000 claims 1
- 108090000144 Human Proteins Proteins 0.000 claims 1
- 102000003839 Human Proteins Human genes 0.000 claims 1
- 102000000646 Interleukin-3 Human genes 0.000 claims 1
- 108090001005 Interleukin-6 Proteins 0.000 claims 1
- 108090000143 Mouse Proteins Proteins 0.000 claims 1
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims 1
- 241000700605 Viruses Species 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 230000001413 cellular effect Effects 0.000 claims 1
- 239000002299 complementary DNA Substances 0.000 claims 1
- 230000000536 complexating effect Effects 0.000 claims 1
- 210000004748 cultured cell Anatomy 0.000 claims 1
- 229940127089 cytotoxic agent Drugs 0.000 claims 1
- 239000000975 dye Substances 0.000 claims 1
- 230000004720 fertilization Effects 0.000 claims 1
- 230000006870 function Effects 0.000 claims 1
- 230000003394 haemopoietic effect Effects 0.000 claims 1
- 239000000710 homodimer Substances 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 238000009413 insulation Methods 0.000 claims 1
- 210000004962 mammalian cell Anatomy 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 238000005259 measurement Methods 0.000 claims 1
- 230000001404 mediated effect Effects 0.000 claims 1
- 230000003658 preventing hair loss Effects 0.000 claims 1
- 210000001236 prokaryotic cell Anatomy 0.000 claims 1
- 230000004936 stimulating effect Effects 0.000 claims 1
- 239000003053 toxin Substances 0.000 claims 1
- 231100000765 toxin Toxicity 0.000 claims 1
- 108700012359 toxins Proteins 0.000 claims 1
- 238000013518 transcription Methods 0.000 claims 1
- 230000035897 transcription Effects 0.000 claims 1
- 238000001890 transfection Methods 0.000 claims 1
- 210000005253 yeast cell Anatomy 0.000 claims 1
- 102000015215 Stem Cell Factor Human genes 0.000 abstract 5
- 238000010188 recombinant method Methods 0.000 abstract 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 2
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 1
- 239000005695 Ammonium acetate Substances 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 229940043376 ammonium acetate Drugs 0.000 description 1
- 235000019257 ammonium acetate Nutrition 0.000 description 1
- 238000005349 anion exchange Methods 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 238000001641 gel filtration chromatography Methods 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 239000001294 propane Substances 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/193—Colony stimulating factors [CSF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/202—IL-3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Toxicology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Cell Biology (AREA)
- General Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Hematology (AREA)
- Pulmonology (AREA)
- Oncology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Diabetes (AREA)
- Virology (AREA)
- Neurosurgery (AREA)
- Communicable Diseases (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US57348390A | 1990-08-27 | 1990-08-27 | |
| US573,483 | 1990-08-27 | ||
| US594,306 | 1990-10-05 | ||
| US07/594,306 US20030125519A1 (en) | 1990-08-27 | 1990-10-05 | Ligand for the c-kit receptor and methods of use thereof |
| PCT/US1991/006130 WO1992003459A1 (en) | 1990-08-27 | 1991-08-27 | LIGAND FOR THE c-KIT RECEPTOR AND METHODS OF USE THEREOF |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR930703339A true KR930703339A (ko) | 1993-11-29 |
Family
ID=27076120
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1019930700578A Ceased KR930703339A (ko) | 1990-08-27 | 1991-08-27 | 씨(c)-키트 수용체의 리간드 및 그의 이용방법 |
Country Status (8)
| Country | Link |
|---|---|
| US (4) | US20030125519A1 (enExample) |
| EP (1) | EP0546054A1 (enExample) |
| JP (1) | JPH06504185A (enExample) |
| KR (1) | KR930703339A (enExample) |
| AU (1) | AU654502B2 (enExample) |
| CA (1) | CA2090469A1 (enExample) |
| HU (1) | HUT64368A (enExample) |
| WO (1) | WO1992003459A1 (enExample) |
Families Citing this family (60)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6852313B1 (en) | 1989-10-16 | 2005-02-08 | Amgen Inc. | Method of stimulating growth of melanocyte cells by administering stem cell factor |
| US7144731B2 (en) * | 1989-10-16 | 2006-12-05 | Amgen Inc. | SCF antibody compositions and methods of using the same |
| JP2657113B2 (ja) * | 1989-10-16 | 1997-09-24 | アムジエン・インコーポレーテツド | 幹細胞因子 |
| US20040181044A1 (en) * | 1989-10-16 | 2004-09-16 | Zsebo Krisztina M. | Method of stimulating growth of epithelial cells by administering stem cell factor |
| US20030125519A1 (en) | 1990-08-27 | 2003-07-03 | Peter Besmer | Ligand for the c-kit receptor and methods of use thereof |
| US20050276784A1 (en) * | 1990-08-27 | 2005-12-15 | Solan-Kettering Institute For Cancer Research | Ligand for the c-kit receptor and methods of use thereof |
| DK0639979T3 (da) * | 1992-04-23 | 2002-12-02 | Sloan Kettering Inst Cancer | Ligand for c-kit-receptoren og fremgangsmåde til anvendelse heraf |
| US5981569A (en) * | 1992-11-13 | 1999-11-09 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Substituted phenylacrylonitrile compounds and compositions thereof for the treatment of disease |
| US5763441A (en) * | 1992-11-13 | 1998-06-09 | Sugen, Inc. | Compounds for the treatment of disorders related to vasculogenesis and/or angiogenesis |
| US5792771A (en) * | 1992-11-13 | 1998-08-11 | Sugen, Inc. | Quinazoline compounds and compositions thereof for the treatment of disease |
| CN1173991C (zh) * | 1992-11-13 | 2004-11-03 | 马克斯普朗克科学促进协会 | 作为血管内皮生长因子受体的f1k-1 |
| US6177401B1 (en) | 1992-11-13 | 2001-01-23 | Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften | Use of organic compounds for the inhibition of Flk-1 mediated vasculogenesis and angiogenesis |
| US5712395A (en) * | 1992-11-13 | 1998-01-27 | Yissum Research Development Corp. | Compounds for the treatment of disorders related to vasculogenesis and/or angiogenesis |
| US6872699B2 (en) | 1992-11-13 | 2005-03-29 | Max-Planck-Gesellschaft Zur Foerderung Der Wissenschaften, E.V. | Truncated Flk-1 receptor protein, methods of use and a recombinant vector containing a nucleotide encoding the truncated Flk-1 protein |
| WO1994019463A2 (en) * | 1993-02-16 | 1994-09-01 | Auckland Uniservices Limited | Developmental tyrosine kinases and their ligands |
| US5525708A (en) * | 1994-03-28 | 1996-06-11 | Cytomed, Inc. | Covalent dimer of kit ligand |
| US6024734A (en) * | 1994-03-31 | 2000-02-15 | Brewitt; Barbara A. | Treatment methods using homeopathic preparations of growth factors |
| GB9515839D0 (en) * | 1995-08-02 | 1995-10-04 | Q One Biotech Ltd | Feline stem cell factor |
| US5885962A (en) * | 1996-04-05 | 1999-03-23 | Amgen Inc. | Stem cell factor analog compositions and method |
| US6734338B1 (en) | 1997-11-14 | 2004-05-11 | Cedars-Sinai Medical Center | Transfection, storage and transfer of male germ cells for generation of transgenic species and genetic therapies |
| CA2309904A1 (en) | 1997-11-14 | 1999-05-27 | Cedars-Sinai Medical Center | Transfection and transfer of male germ cells for generation of transgenic species |
| US7294755B1 (en) | 1997-11-14 | 2007-11-13 | Cedars-Sinai Medical Center | Genetic modification of male germ cells for generation of transgenic species and genetic therapies |
| JP2003525581A (ja) * | 1998-11-13 | 2003-09-02 | セダーシナイ メディカル センター | 脊椎動物精巣の細胞減失（ｄｅｐｏｐｕｌａｔｉｎｇ）方法およびトランスジェニック種の作製方法 |
| AU3563499A (en) * | 1998-11-13 | 2000-06-05 | Cedars-Sinai Medical Center | Transfection of male germ cells for generation of selectable transgenic stem cells |
| FR2853663B1 (fr) * | 2003-04-14 | 2007-08-31 | Aventis Pharma Sa | Procede d'obtention de lignees de mastocytes a partir de tissus de porcs et procede de production de molecules de type heparine |
| US20060153799A1 (en) | 2004-11-05 | 2006-07-13 | Northwestern University | Use of SCF and G-CSF in the treatment of cerebral ischemia and neurological disorders |
| EP1877547B1 (en) | 2005-05-04 | 2012-08-08 | Commonwealth Scientific and Industrial Research Organisation | Selecting, culturing and creating lineage committed hematopoietic stem cells |
| AU2006315601A1 (en) * | 2005-11-14 | 2007-05-24 | Enterprise Partners Venture Capital | Stem cell factor therapy for tissue injury |
| WO2007149493A2 (en) * | 2006-06-22 | 2007-12-27 | Immugen Inc | Restoration of hearing loss |
| CA2677273A1 (en) * | 2007-02-06 | 2008-08-14 | Tai-June Yoo | Use of a composition comprising a cytokine encoding nucleic acid for treating alzheimer's disease |
| DK2668210T3 (da) | 2011-01-26 | 2020-08-24 | Celldex Therapeutics Inc | Anti-kit antistoffer og anvendelser deraf |
| KR101384360B1 (ko) * | 2012-05-04 | 2014-04-14 | 아주대학교산학협력단 | Ｓｃｆ 또는 이의 수용체를 억제하는 물질을 포함하는 혈관 투과성 관련 질환의 치료 또는 예방용 조성물 |
| WO2014018625A1 (en) | 2012-07-25 | 2014-01-30 | Kolltan Pharmaceuticals, Inc. | Anti-kit antibodies and uses thereof |
| CN113975386A (zh) | 2014-05-23 | 2022-01-28 | 塞尔德克斯医疗公司 | 嗜酸性粒细胞或肥大细胞相关病症的治疗 |
| IL294032A (en) | 2019-12-24 | 2022-08-01 | Carna Biosciences Inc | Compounds that regulate diacylglycerol kinase |
| EP4103285A2 (en) | 2020-02-14 | 2022-12-21 | Jounce Therapeutics, Inc. | Antibodies and fusion proteins that bind to ccr8 and uses thereof |
| CN117355531A (zh) | 2021-06-23 | 2024-01-05 | 吉利德科学公司 | 二酰基甘油激酶调节化合物 |
| EP4359413A1 (en) | 2021-06-23 | 2024-05-01 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| CN117377671A (zh) | 2021-06-23 | 2024-01-09 | 吉利德科学公司 | 二酰基甘油激酶调节化合物 |
| CA3220923A1 (en) | 2021-06-23 | 2022-12-29 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| JP2024539252A (ja) | 2021-10-28 | 2024-10-28 | ギリアード サイエンシーズ， インコーポレイテッド | ピリジジン－３（２ｈ）－オン誘導体 |
| PE20241186A1 (es) | 2021-10-29 | 2024-06-03 | Gilead Sciences Inc | Compuestos de cd73 |
| JP2024546851A (ja) | 2021-12-22 | 2024-12-26 | ギリアード サイエンシーズ， インコーポレイテッド | Ｉｋａｒｏｓジンクフィンガーファミリー分解剤及びその使用 |
| CA3237577A1 (en) | 2021-12-22 | 2023-06-29 | Gilead Sciences, Inc. | Ikaros zinc finger family degraders and uses thereof |
| TW202340168A (zh) | 2022-01-28 | 2023-10-16 | 美商基利科學股份有限公司 | Ｐａｒｐ７抑制劑 |
| PL4245756T3 (pl) | 2022-03-17 | 2025-02-17 | Gilead Sciences, Inc. | Środki degradujące palec cynkowy z rodziny ikaros i ich zastosowania |
| CA3249472A1 (en) | 2022-04-21 | 2023-10-26 | Gilead Sciences, Inc. | KIRSTEN G12D RAT SARCOMA VIRUS MODULATOR COMPOUNDS |
| AU2023298558A1 (en) | 2022-07-01 | 2024-12-19 | Gilead Sciences, Inc. | Cd73 compounds |
| CN120225509A (zh) | 2022-12-22 | 2025-06-27 | 吉利德科学公司 | Prmt5抑制剂及其用途 |
| CN120882725A (zh) | 2023-04-11 | 2025-10-31 | 吉利德科学公司 | Kras调节化合物 |
| KR20250175331A (ko) | 2023-04-21 | 2025-12-16 | 길리애드 사이언시즈, 인코포레이티드 | Prmt5 억제제 및 이의 용도 |
| AU2024306338A1 (en) | 2023-06-30 | 2026-01-08 | Gilead Sciences, Inc. | Kras modulating compounds |
| WO2025024811A1 (en) | 2023-07-26 | 2025-01-30 | Gilead Sciences, Inc. | Parp7 inhibitors |
| US20250066328A1 (en) | 2023-07-26 | 2025-02-27 | Gilead Sciences, Inc. | Parp7 inhibitors |
| EP4516807A1 (en) | 2023-08-28 | 2025-03-05 | Consorcio Centro de Investigación Biomédica en Red | Compositions for use in a method of providing improved hematopoietic stem cell engraftment |
| US20250109147A1 (en) | 2023-09-08 | 2025-04-03 | Gilead Sciences, Inc. | Kras g12d modulating compounds |
| US20250101042A1 (en) | 2023-09-08 | 2025-03-27 | Gilead Sciences, Inc. | Kras g12d modulating compounds |
| US20250154172A1 (en) | 2023-11-03 | 2025-05-15 | Gilead Sciences, Inc. | Prmt5 inhibitors and uses thereof |
| US20250230168A1 (en) | 2023-12-22 | 2025-07-17 | Gilead Sciences, Inc. | Azaspiro wrn inhibitors |
| WO2025245003A1 (en) | 2024-05-21 | 2025-11-27 | Gilead Sciences, Inc. | Prmt5 inhibitors and uses thereof |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5399493A (en) | 1989-06-15 | 1995-03-21 | The Regents Of The University Of Michigan | Methods and compositions for the optimization of human hematopoietic progenitor cell cultures |
| DE69034258D1 (de) * | 1989-10-16 | 2008-09-18 | Amgen Inc | Stamzellfaktor |
| WO1991014767A1 (en) | 1990-03-23 | 1991-10-03 | Ludwig Institute For Cancer Research | Method for enhanced growth and proliferation of mast cells |
| WO1992000376A1 (en) * | 1990-06-25 | 1992-01-09 | Immunex Corporation | Mast cell growth factor |
| US20030125519A1 (en) | 1990-08-27 | 2003-07-03 | Peter Besmer | Ligand for the c-kit receptor and methods of use thereof |
| US5767074A (en) | 1990-08-27 | 1998-06-16 | Sloan-Kettering Institute For Cancer Research | Compositions of soluble C-kit ligand and hematopoietic factors |
| AU9028791A (en) | 1990-10-05 | 1992-04-28 | President And Fellows Of Harvard College | Detection and isolation of ligands |
| US5409825A (en) | 1991-04-09 | 1995-04-25 | Indiana University Foundation | Expansion of human hematopoietic progenitor cells in a liquid medium |
| US5199942A (en) | 1991-06-07 | 1993-04-06 | Immunex Corporation | Method for improving autologous transplantation |
| US6001803A (en) | 1992-04-23 | 1999-12-14 | Sloan-Kettering Institute For Cancer Research | Composition of c-kit ligand, GM-CSF, and TNF-α and method of use |
-
1990
- 1990-10-05 US US07/594,306 patent/US20030125519A1/en not_active Abandoned
-
1991
- 1991-08-27 KR KR1019930700578A patent/KR930703339A/ko not_active Ceased
- 1991-08-27 JP JP3515137A patent/JPH06504185A/ja active Pending
- 1991-08-27 CA CA002090469A patent/CA2090469A1/en not_active Abandoned
- 1991-08-27 EP EP91916054A patent/EP0546054A1/en not_active Withdrawn
- 1991-08-27 HU HU9300541A patent/HUT64368A/hu unknown
- 1991-08-27 WO PCT/US1991/006130 patent/WO1992003459A1/en not_active Ceased
- 1991-08-27 AU AU85106/91A patent/AU654502B2/en not_active Withdrawn - After Issue
-
1995
- 1995-06-07 US US08/478,414 patent/US5935565A/en not_active Expired - Lifetime
-
1999
- 1999-08-10 US US09/371,261 patent/US6403559B1/en not_active Expired - Fee Related
-
2002
- 2002-04-24 US US10/132,345 patent/US20030103937A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| HUT64368A (en) | 1993-12-28 |
| HU9300541D0 (en) | 1993-05-28 |
| US5935565A (en) | 1999-08-10 |
| AU654502B2 (en) | 1994-11-10 |
| US20030125519A1 (en) | 2003-07-03 |
| US6403559B1 (en) | 2002-06-11 |
| AU8510691A (en) | 1992-03-17 |
| CA2090469A1 (en) | 1992-02-28 |
| WO1992003459A1 (en) | 1992-03-05 |
| EP0546054A1 (en) | 1993-06-16 |
| EP0546054A4 (enExample) | 1994-04-27 |
| JPH06504185A (ja) | 1994-05-19 |
| US20030103937A1 (en) | 2003-06-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR930703339A (ko) | 씨(c)-키트 수용체의 리간드 및 그의 이용방법 | |
| Metcalf et al. | In vitro actions on hemopoietic cells of recombinant murine GM‐CSF purified after production in Escherichia coli: Comparison with purified native GM‐CSF | |
| D'Amore et al. | Endothelial cell mitogens derived from retina and hypothalamus: biochemical and biological similarities. | |
| Lemke et al. | Identification and purification of glial growth factor | |
| Jackson et al. | Heat shock induces the release of fibroblast growth factor 1 from NIH 3T3 cells. | |
| KR100205078B1 (ko) | 염기성 섬유 아세포 성장인자 및 이의 생산방법 | |
| US5767078A (en) | Agonist peptide dimers | |
| AU667996B2 (en) | Modified ciliary neurotrophic factors | |
| AU721196B2 (en) | Circularly permuted erythropoietin receptor agonists | |
| KR101160381B1 (ko) | 생체내에서 조혈 자극제로서 사용하기 위한 재조합 ｔａｔ-ｈｏｘｂ４ｈ 단백질의 제조 방법 | |
| JP2704512B2 (ja) | インターリューキン−２およびその純化方法 | |
| JPH05503512A (ja) | 白血球接着阻害因子としての［ａｌａ ｉｌ―８］↓７↓７ | |
| EP0427189A1 (en) | Modified forms of human erythropoietin and DNA sequences encoding genes which can express them | |
| Seno et al. | Purification and characterization of a recombinant human cripto-1 protein | |
| Fujimoto et al. | Purification of megakaryocyte differentiation activity from a human fibrous histiocytoma cell line: N-terminal sequence homology with activin A | |
| AU689560B2 (en) | Method for stimulating profileration of colon cells using POMC-76-103 | |
| AU2008256550B2 (en) | VEGF-D mutants and their use | |
| KR20230155484A (ko) | 융합 단백질의 제조 방법 | |
| JP7671243B2 (ja) | 修飾ヒトエリスロポエチン（ｍｏｄｉｆｉｅｄ ｈｕｍａｎ ｅｒｙｔｈｒｏｐｏｉｅｔｉｎ） | |
| BR9708648B1 (pt) | polipeptìdeo, molécula de dna, vetor, processo para a produção do polipeptìdeo, e composição farmacêutica. | |
| RU2827791C2 (ru) | Модифицированный эритропоэтин человека | |
| CN111825770B (zh) | 长效白介素21-Fc融合蛋白及其用途 | |
| AU2005244575B2 (en) | Human Vascular Endothelial Growth Factor 2 | |
| JP2001511641A (ja) | インターロイキン―５のアンタゴニスト | |
| EP0308424A1 (en) | A novel protein, neuroleukin |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0109 | Patent application |
Patent event code: PA01091R01D Comment text: Patent Application Patent event date: 19930226 |
|
| PG1501 | Laying open of application | ||
| A201 | Request for examination | ||
| PA0201 | Request for examination |
Patent event code: PA02012R01D Patent event date: 19960821 Comment text: Request for Examination of Application Patent event code: PA02011R01I Patent event date: 19930226 Comment text: Patent Application |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 19981231 Patent event code: PE09021S01D |
|
| E601 | Decision to refuse application | ||
| PE0601 | Decision on rejection of patent |
Patent event date: 19990326 Comment text: Decision to Refuse Application Patent event code: PE06012S01D Patent event date: 19981231 Comment text: Notification of reason for refusal Patent event code: PE06011S01I |